Le Lézard
Classified in: Health, Business
Subjects: OFR, VEN

LISCure Biosciences Successfully Raises $21 million in Series B Funding


SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, announced that it has successfully completed $21 million of a Series B funding round. Participants include institutional investors, venture capitals, and KOSDAQ listed companies (as strategic investors).

"This investment was made after reviewing the promising pre-clinical results of LISCure's new drug candidates for each indication and we verified its potential as a new therapeutic treatment. Based on the technologies of both companies, we will actively cooperate in research and development for these innovative new drug candidates in the microbiome field", one of the strategic investors said.

LISCure Biosciences's pipeline

This funding round will help LISCure further develop its pipeline and enhance its R&D capabilities of key technologies. LISCure uses a single strain approach whose strain is a naturally derived as well as non-pathogenic substance so it has a great advantage over other microbiome competitors in terms of safety. LISCure is developing the world's first microbiome-based NASH(non-alcoholic steatohepatitis) treatment, LB-P8, as well as the rheumatoid arthritis treatment, LB-P6, for global clinical trials.

LISCure's drug candidates have already been tested for efficacy and safety by a third CRO, and the four of the candidates have been completed the process development by CDMO based in the United States. Two of the candidates are currently in the process of cGMP manufacturing under CDMO based in France. LISCure is expecting the four lead candidates to enter global clinical trials in the next two years and possibly begin phase 2 with two of the candidates. In addition to the funding, LISCure has completed the establishment of corporations in the US and Australia for global clinical development. LISCure is planning to expand indications of each program through the US subsidy, working with global top research institutes.

About LISCure Biosciences

Founded in 2018, LISCure Biosciences was established to develop a "bacteria-mediated immunotherapy" that can treat patients by itself or be used in combination with other drugs for major indications such as tumors, neurological degeneration, autoimmune, and metabolic diseases.

 

SOURCE LISCure Biosciences Co., Ltd.


These press releases may also interest you

at 15:14
Kiosk Operators LLC (KO) Acquires Wellmation, Facilitating Advancement in Patient access to Health Care and Pharmaceuticals
KO, a leading provider of innovative kiosk and locker solutions, has announced its acquisition of Wellmation, a pioneering company in pharmaceutical kiosks. The acquisition includes Wellmation's patents, software, hardware, and general intellectual...

at 15:05
NEWPORT NEWS PAIN PHYSICIAN PERFORMS FIRST SI JOINT FUSION IN VA, MD, & DC AREA USING LINQ SYSTEM
On Wednesday, Interventional Pain Management Physician Raj Sureja, MD, performed the first sacroiliac (SI) joint fusion in Virginia, Maryland, and DC, using the PainTEQ LinQ SI Joint Stabilization System. https://www.painteq.com/procedure This...

at 15:00
During Oral Cancer Awareness Month, AANA Emphasizes Access to Safe Dental Anesthesia Care
(AANA) ?April is Oral Cancer Awareness Month, and the American Association of Nurse Anesthesiology (AANA) reminds the public that the best prevention of oral health issues is early detection. However, patients also need to be aware of the critical...

at 14:55
NIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
What: In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person's cancer will respond to a...

at 14:43
Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder
The Global PTSD Genetics initiative founded in 2015 by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Research at Broad Institute, and the Psychiatric Genomics Consortium today announces a pivotal milestone in the genetics of...

at 14:39
Ontario Human Rights Commission announces development of policy to address Indigenous-specific discrimination in Ontario's healthcare system
Today, the Ontario Human Rights Commission (OHRC) announced its commitment to work with Indigenous partners to develop human rights policy guidance to address and combat long-standing and widespread Indigenous-specific discrimination in Ontario's...

More news about Health...


News published on and distributed by: